LOT 1303663 / EXP 28/05/2028 pour le stock actuel
The clinical data, dosing schedules, and medication information presented on this page have been reviewed for accuracy against FDA prescribing information and published trial results
Novo Nordisk has responded by planning a higher-dose CagriSema trial (REDEFINE 11), expected to report in early 2027, and by filing an NDA at the current dose
But right now, unfortunately, it is unsustainable. The states biggest private insurer, Blue Cross Blue Shield of Massachusetts, also axed coverage of GLP-1 drugs for weight loss this year because the costs were driving up premiums for all members
Allergic Reactions Though rare, some may experience rash, swelling, or breathing difficulties
Tirzepatide works similarly but also targets another receptor called GIP